We are live on ! Find out more
GT

Glenmede Trust Portfolio holdings

AUM $20.4B
This Fund
S&P 500
This Quarter Est. Return
+8.99%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$21.9B
AUM Growth
+$21.9B
Cap. Flow
-$417M
Cap. Flow %
-1.9%
Top 10 Hldgs %
13.08%
Holding
3,337
New
135
Increased
1,103
Reduced
1,007
Closed
163

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$89.3M
2
KEYS icon
Keysight
KEYS
+$86M
3
NKE icon
Nike
NKE
+$78.3M
4
APH icon
Amphenol
APH
+$76.5M
5
CMCSA icon
Comcast
CMCSA
+$72.3M

Top Sells

Rank Stock Value
1
CE icon
Celanese
CE
+$108M
2
MNST icon
Monster Beverage
MNST
+$97.8M
3
SBUX icon
Starbucks
SBUX
+$79.7M
4
TXN icon
Texas Instruments
TXN
+$67.3M
5
CNC icon
Centene
CNC
+$64.3M

Sector Composition

Rank Sector Weight
1 Technology 18.83%
2 Financials 13.42%
3 Healthcare 13.25%
4 Industrials 9.77%
5 Consumer Discretionary 7.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
POWL icon
2226
Powell Industries
POWL
$7.34B
$4K ﹤0.01%
261
– –
HTT
2227
High Templar Tech Ltd
HTT
$382M
$4K ﹤0.01%
+1,000
New +$5.88K
QNST icon
2228
QuinStreet
QNST
$923M
$4K ﹤0.01%
301
– –
RGA icon
2229
Reinsurance Group of America
RGA
$15.9B
$4K ﹤0.01%
28
– –
SAFE
2230
Safehold
SAFE
$1.2B
$4K ﹤0.01%
65
– –
SPB icon
2231
Spectrum Brands
SPB
$2.07B
$4K ﹤0.01%
+77
New +$4.36K
SXC icon
2232
SunCoke Energy
SXC
$783M
$4K ﹤0.01%
891
-2,015
-69% -$11.2K
TDC icon
2233
Teradata
TDC
$2.81B
$4K ﹤0.01%
150
-274
-65% -$7.62K
TEI
2234
Templeton Emerging Markets Income Fund
TEI
$314M
$4K ﹤0.01%
500
– –
TSLX icon
2235
Sixth Street Specialty
TSLX
$1.67B
$4K ﹤0.01%
200
– –
UCTT
2236
Ultra Clean Holdings
UCTT
$3.48B
$4K ﹤0.01%
209
+136
+186% +$2.75K
UIS icon
2237
Unisys
UIS
$254M
$4K ﹤0.01%
381
-74
-16% -$742
VECO icon
2238
Veeco
VECO
$2.79B
$4K ﹤0.01%
287
– –
WOLF icon
2239
Wolfspeed
WOLF
$1.12B
$4K ﹤0.01%
107
+66
+161% +$3.08K
WWD icon
2240
Woodward
WWD
$24.3B
$4K ﹤0.01%
37
– –
ONC
2241
BeOne Medicines Ltd
ONC
$34B
$4K ﹤0.01%
29
+2
+7% +$332
NVRO
2242
DELISTED
NEVRO CORP.
NVRO
$4K ﹤0.01%
40
– –
EGRX
2243
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$4K ﹤0.01%
76
– –
ITCL
2244
DELISTED
Banco Itau Chile American Depositary Shares (each representing one third of one (1/3) Common Share)
ITCL
$4K ﹤0.01%
512
– –
DBD
2245
DELISTED
Diebold Nixdorf Incorporated
DBD
$4K ﹤0.01%
466
– –
CVA
2246
DELISTED
Covanta Holding Corporation
CVA
$4K ﹤0.01%
331
-64
-16% -$976
LDL
2247
DELISTED
Lydall, Inc.
LDL
$4K ﹤0.01%
228
-64
-22% -$1.32K
RP
2248
DELISTED
RealPage, Inc.
RP
$4K ﹤0.01%
+85
New +$4.84K
MIK
2249
DELISTED
Michaels Stores, Inc
MIK
$4K ﹤0.01%
+665
New +$5.59K
SINA
2250
DELISTED
Sina Corp
SINA
$4K ﹤0.01%
124
-132
-52% -$5.06K
88 89
90
91 92

Similar funds

SLAM
Swiss Life Asset Management Zurich $20.4B AUM 28.71% 1-Year Est. Return
EWA
EP Wealth Advisors Torrance, California $20.3B AUM
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
P
&Partners Nashville, Tennessee $20.2B AUM 19.79% 1-Year Est. Return
CI Investments Inc
CI Investments Inc Toronto, Ontario, Canada $20.6B AUM 29.22% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $20.1B AUM 30.42% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return
EIM
Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Glenmede Trust's Q4 2019 Portfolio in Review

As of Q4 2019, Glenmede Trust held 3,337 positions worth $21.9B, up 100,205% from $21.9M the previous quarter. Its ten largest holdings account for 13% of the portfolio.

Glenmede Trust's Q4 2019 filing shows 135 new, 1,103 increased, 1,007 reduced and 163 closed positions. Its largest new stake was Callon Petroleum Company: 285,674 shares worth $13.8M. The largest sale was Celanese, an estimated $108M.

By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 17% a quarter earlier, followed by Financials and Healthcare.

  • Glenmede Trust's largest Q4 2019 buy was Callon Petroleum Company: 285,674 shares worth $13.8M.
  • Glenmede Trust added most to Bristol-Myers Squibb in Q4 2019, an estimated $89.3M increase.
  • Glenmede Trust's biggest Q4 2019 reduction was Celanese, cutting an estimated $108M.
  • Glenmede Trust fully exited Celgene Corp in Q4 2019, selling an estimated $122K.
  • Glenmede Trust's ten largest holdings make up 13% of its $21.9B portfolio in Q4 2019.
  • Glenmede Trust opened 135 new positions and closed 163 in Q4 2019.
  • Glenmede Trust's portfolio value rose 100,205% quarter-over-quarter to $21.9B.

Based on Glenmede Trust's 13F filing for Q4 2019, filed 12 Feb 2020.